In February 2017, the CEO of Tillotts Pharma AG, Thomas A. Tóth von Kiskér, was interviewed for the special edition of “Healthcare & Life Sciences Review Switzerland”. Part of the interview will be featured in the 2017-spring edition of Pharmaceutical Executive Magazine and the full interview is available on pharmaboardroom.com, an online platform aimed at C-level executives, consultants, regulators and vendors working in Healthcare Life Sciences globally.
An excerpt of the interview can be found below. The full interview is available here (NB! A login needs to be created free of charge).
Backed by the Japanese Zeria Group, fast growing gastrointestinal (GI) specialist Tillotts Pharma is, after its recent US$ 200m M&A deal, looking to acquire further GI assets generating a turnover of € 50m - € 150 million in Europe and/or Japan, and also to enter into a strategic partnership with a GI focused US based company. CEO Thomas A. Tóth von Kiskér discusses some of the barriers to growth that SMEs face today in an increasingly consolidated industry.
As the CEO of Tillotts Pharma – a GI focused Swiss pharma company with about 300 employees – what would you highlight as some of the greatest barriers to growth which you must work to overcome?
SMEs are increasingly facing an environment which features significant barriers for smaller players, where companies without a certain size and financing capacity may find it difficult to compete. This becomes clear when looking at the challenge of building a pipeline, which ultimately any pharma company that wants to grow, or avoid seeing revenues decline, must do to balance out the effect of patent expiration and the introduction of newer, more effective competing products. There are two ways companies can fill their pipeline with new products, either by in-licensing/M&A, or developing them internally.
From a product development perspective, as regulatory hurdles are constantly increasing, so is the price of the development: the average cost of developing a new chemical entity has surpassed USD 1.5 billion. With that in mind, many small companies are being pushed to riskier and riskier areas of innovation, and some have been very successful, but here the mentality and business model has shifted towards the eventual goal of going public via an IPO or being acquired.